229 related articles for article (PubMed ID: 32569821)
21. Multicellular spheroids from normal and neoplastic thyroid tissues as a suitable model to test the effects of multikinase inhibitors.
Cirello V; Vaira V; Grassi ES; Vezzoli V; Ricca D; Colombo C; Bosari S; Vicentini L; Persani L; Ferrero S; Fugazzola L
Oncotarget; 2017 Feb; 8(6):9752-9766. PubMed ID: 28039458
[TBL] [Abstract][Full Text] [Related]
22. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
23. Aggressive variants of follicular cell derived thyroid carcinoma; the so called 'real thyroid carcinomas'.
Baloch Z; LiVolsi VA; Tondon R
J Clin Pathol; 2013 Sep; 66(9):733-43. PubMed ID: 23626010
[TBL] [Abstract][Full Text] [Related]
24. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers.
Schweppe RE; Pozdeyev N; Pike LA; Korch C; Zhou Q; Sams SB; Sharma V; Pugazhenthi U; Raeburn C; Albuja-Cruz MB; Reigan P; LaBarbera DV; Landa I; Knauf JA; Fagin JA; Haugen BR
Mol Cancer Res; 2019 May; 17(5):1036-1048. PubMed ID: 30733375
[TBL] [Abstract][Full Text] [Related]
25. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
Filetti S; Durante C; Hartl D; Leboulleux S; Locati LD; Newbold K; Papotti MG; Berruti A;
Ann Oncol; 2019 Dec; 30(12):1856-1883. PubMed ID: 31549998
[No Abstract] [Full Text] [Related]
26. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
Oh JM; Baek SH; Gangadaran P; Hong CM; Rajendran RL; Lee HW; Zhu L; Gopal A; Kalimuthu S; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2020 Apr; 30(4):501-518. PubMed ID: 31928162
[No Abstract] [Full Text] [Related]
27. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
[TBL] [Abstract][Full Text] [Related]
28. Spinal metastases due to thyroid carcinoma: an analysis of 202 patients.
Kushchayeva YS; Kushchayev SV; Carroll NM; Felger EA; Links TP; Teytelboym OM; Bonichon F; Preul MC; Sonntag VK; Van Nostrand D; Burman KD; Boyle LM
Thyroid; 2014 Oct; 24(10):1488-500. PubMed ID: 24921429
[TBL] [Abstract][Full Text] [Related]
29. Expression of MicroRNAs in Thyroid Carcinoma.
Zhu G; Xie L; Miller D
Methods Mol Biol; 2017; 1617():261-280. PubMed ID: 28540691
[TBL] [Abstract][Full Text] [Related]
30. New Insights into Immune Cells and Immunotherapy for Thyroid Cancer.
Tao Y; Li P; Feng C; Cao Y
Immunol Invest; 2023 Nov; 52(8):1039-1064. PubMed ID: 37846977
[TBL] [Abstract][Full Text] [Related]
31. Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer.
van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
Thyroid; 2018 Aug; 28(8):976-981. PubMed ID: 29848239
[TBL] [Abstract][Full Text] [Related]
32. Contemporary management of thyroid cancer.
Blankenship DR; Chin E; Terris DJ
Am J Otolaryngol; 2005; 26(4):249-60. PubMed ID: 15991091
[TBL] [Abstract][Full Text] [Related]
33. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.
Francis GL; Waguespack SG; Bauer AJ; Angelos P; Benvenga S; Cerutti JM; Dinauer CA; Hamilton J; Hay ID; Luster M; Parisi MT; Rachmiel M; Thompson GB; Yamashita S;
Thyroid; 2015 Jul; 25(7):716-59. PubMed ID: 25900731
[TBL] [Abstract][Full Text] [Related]
34. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.
Molinaro E; Romei C; Biagini A; Sabini E; Agate L; Mazzeo S; Materazzi G; Sellari-Franceschini S; Ribechini A; Torregrossa L; Basolo F; Vitti P; Elisei R
Nat Rev Endocrinol; 2017 Nov; 13(11):644-660. PubMed ID: 28707679
[TBL] [Abstract][Full Text] [Related]
35. CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors.
Min IM; Shevlin E; Vedvyas Y; Zaman M; Wyrwas B; Scognamiglio T; Moore MD; Wang W; Park S; Park S; Panjwani S; Gray KD; Tassler AB; Zarnegar R; Fahey TJ; Jin MM
Clin Cancer Res; 2017 Dec; 23(24):7569-7583. PubMed ID: 29025766
[No Abstract] [Full Text] [Related]
36. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
[TBL] [Abstract][Full Text] [Related]
37. The treatment and prognosis of Hürthle cell follicular thyroid carcinoma compared with its non-Hürthle cell counterpart.
Haigh PI; Urbach DR
Surgery; 2005 Dec; 138(6):1152-7; discussion 1157-8. PubMed ID: 16360403
[TBL] [Abstract][Full Text] [Related]
38. Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy.
San Román Gil M; Pozas J; Molina-Cerrillo J; Gómez J; Pian H; Pozas M; Carrato A; Grande E; Alonso-Gordoa T
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668761
[TBL] [Abstract][Full Text] [Related]
39. Comparison of malignancy rate in thyroid nodules with cytology of indeterminate follicular or indeterminate Hürthle cell neoplasm.
Sorrenti S; Trimboli P; Catania A; Ulisse S; De Antoni E; D'Armiento M
Thyroid; 2009 Apr; 19(4):355-60. PubMed ID: 19355826
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and incidence of cytoplasmic yellow bodies in thyroid neoplasms.
Rothenberg HJ; Goellner JR; Carney JA
Arch Pathol Lab Med; 2003 Jun; 127(6):715-7. PubMed ID: 12741896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
